Sobrevida e fatores associados em pacientes com câncer de mama, com diagnóstico entre 2003 e 2005 no munícipio de Juiz de Fora – Minas Gerais

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Universidade Federal de Juiz de Fora

DOI

Abstract

Purpose: Analyze the 5-year breast cancer specific-survival rate and according to the immunohistochemical profile of women diagnosed with breast cancer. Methods: The population was composed from a hospital-based cohort of all women diagnosed with breast cancer between 2003 and 2005 (n= 563), and treated at cancer care reference center in the city of Juiz de Fora/MG, Brazil. Survival time was counted from the date of the histopathological diagnosis and the date of death due to breast cancer was considered the adverse event. Women alive until December 2010, the final date of the follow-up, were censored. For those who interrupt treatment, censor date was the last follow-up in the medical records. Kaplan-Meier survival curves were estimated, and multivariate analysis was performed by the Cox proporciona hazard model. Results: Mean age was 58,05 years, and the majority were white skin color (81,1%) and postmenopausal (66,8%). Clinical Stages II (36,7%) and III (25,3%) predominated. The most common subtypes were luminal A (n= 295 cases – 52,4%) and cases with unknown profile (n= 107 – 19%) Breast cancer specific five-year survival rate was 79,93%. A better unadjusted survival was observed among women with disease diagnostic, immunohistochemical subtypes luminal A and B (p<0,0001), white skin color (p<0,0001), with tumor size ≤ 2.0cm (p<0,0001), without lymph node involvement (p<0,0001), in a less advanced disease stage (p<0,001), and of systemic treatment (p=0,01), and who used hormone therapy (p<0.0001). The main prognostic factors associated with poor survival were: subtypes triple negative (p<0.001), HER2 overexpression (p=0.01) and immunohistochemical profile unknown (p=0.01), no white race (p=0.02), advanced disease (stage III and IV – p<0.001), no realization of systemic treatment (p=0.009) and no use of first line chemotherapy (p=0.09). Conclusion: This research allowed identification of the profile and disease survival of breast cancer patients, according to imunohistochemical profile.

Description

Citation

Endorsement

Review

Supplemented By

Referenced By

Rights and licensing

Acesso Aberto